A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 211 Administered as Continuous Intravenous Infusion in Subjects With Relapsed/Refractory Gastrointestinal Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2017
At a glance
- Drugs MEDI 565 (Primary)
- Indications Adenocarcinoma; Gastrointestinal cancer
- Focus Adverse reactions
- Sponsors Amgen
- 18 Sep 2017 Planned End Date changed from 5 Oct 2017 to 30 Jan 2018.
- 25 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Jan 2017 Planned End Date changed from 1 Jul 2017 to 1 Oct 2017.